Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 129 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Experimental Cancer Drug Metarrestin Targets Metastatic Tumors May 29, 2018 New plan unveiled to tackle Scotland’s cancer crisis June 16, 2023 Many Older Adults Screened Unnecessarily for Common Cancers August 27, 2020 FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour April 4, 2025 Load more HOT NEWS Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor... Dad With Cancer Escorts His Autistic Son To School, With The... FDA Approves Pralsetinib for Lung Cancer with RET Gene Fusions Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive...
